Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-Patients with chronic myeloid leukemia in the chronic phase diagnosed within 6 months of study entry~Exclusion Criteria:~* Treatment with tyrosine kinase inhibitor or other antileukemic agents or treatments (including HSCT) for longer than 2 weeks, with exception of hydroxyurea and/or anagrelide~* Uncontrolled congestive heart failure or hypertension~* Myocardial infarction or unstable angina pectoris within past 12 months~* Known T315I mutations~* QTcF \>450 msec~* Significant arrhythmias~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): 300 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).